Mercado mundial de tratamiento de la distrofia muscular de Duchenne, por tipo de tratamiento (terapias basadas en moléculas, terapia con esteroides y otras), terapia (enfoque de omisión de exones, supresión de mutaciones y terapias dirigidas a la distrofina), vía de administración (oral, parenteral y otras), usuario final (hospitales, clínicas especializadas, atención domiciliaria y otros), canal de distribución (farmacia hospitalaria, farmacia minorista y farmacia en línea): tendencias de la industria y pronóstico hasta 2030.
Duchenne Muscular Dystrophy Tratamiento Análisis del mercado y tamaño
Los principales factores esperados para impulsar el crecimiento del mercado son la conciencia creciente del tratamiento de DMD y la introducción de nuevas terapias para el trastorno de DMD. Además, el aumento de la prevalencia y el impacto del trastorno DMD son otro factor clave que se espera impulsar el crecimiento del mercado. Un aumento en el número de ensayos clínicos es una tendencia reciente también se espera impulsar el crecimiento del mercado. Sin embargo, se espera que la disponibilidad limitada del tratamiento de DMD debido a la tecnología avanzada y al elevado costo de tratamiento del trastorno de DMD restrinja el crecimiento del mercado.
Data Bridge Market Research analiza que se espera que el mercado mundial de tratamiento de distrofia muscular duchena llegue a USD 8.654.688.51mil para 2030, en una CAGR de 16.8% durante el período de previsión 2023-2030. Este informe de mercado también abarca en profundidad el análisis de precios y los avances tecnológicos.
|
Informe métrico |
Detalles |
|
Período de predicción |
2023 a 2030 |
|
Año base |
2022 |
|
Años históricos |
2021 (Customizable to 2015 - 2020) |
|
Unidades cuantitativas |
Ingresos en USD Mil |
|
Segmentos cubiertos |
Tipo de Tratamiento (Terapias de base molecular, Terapia esteroidea y otras), Terapia (Exon Skipping Approach, Mutation Suppression, and Dystrophin-Targeted Therapies), Ruta de Administración (Oral, Parenteral y Otros), Usuario final (Hospitals, Clínicas de Especialidad, Homecare y Otros), Canal de Distribución (Farmacia Farmacéutica Retail |
|
Países cubiertos |
Estados Unidos, Canadá, México, Alemania, Francia, Reino Unido, Italia, España, Rusia, Turquía, Bélgica, Países Bajos, Suiza, resto de Europa, Japón, China, Corea del Sur, India, Australia, Singapur, Tailandia, Malasia, Indonesia, Filipinas, resto de Asia-Pacífico, Brasil, Argentina, resto de América del Sur, Sudáfrica, Arabia Saudita, Emiratos Árabes Unidos, Egipto, Israel y resto de Oriente Medio y África |
|
Jugadores de mercado cubiertos |
Sarepta Therapeutics, Inc., GSK plc., Capricor Therapeutics, Inc., Dyne Therapeutics, Solid Biosciences Inc., BioMarin, Stealth BioTherapeutics Inc., Avidity Biosciences, ReveraGen BioPharma, Inc. PTC Therapeutics, NS Pharma, Inc, ITALFARMACO S.p. |
Definición
Duchenne La distrofia muscular (DMD) es un trastorno genético raro caracterizado por la degeneración y debilidad muscular progresivas. El tratamiento primario para DMD implica el uso de corticosteroides, como prednisona o deflazacort. Estos medicamentos ayudan a reducir la inflamación y retrasar la degeneración muscular, prolongando finalmente la capacidad de caminar y preservar la función muscular. Se ha demostrado que el tratamiento corticosteroides mejora la fuerza muscular, la función respiratoria y la calidad general de vida en individuos con DMD.
Global Duchenne Muscular Dystrophy Treatment Market Dynamics
Esta sección trata de entender los factores de mercado, ventajas, restricciones y desafíos. Todo esto se discute en detalle a continuación:
Conductores
- Aumento de la prevalencia y el impacto de la distrofia muscular de Duchenne (DMD) enfermedad
Duchenne La distrofia muscular (DMD) es un trastorno genético poco frecuente y debilitante caracterizado por debilidad muscular progresiva y pérdida de la función. Afecta principalmente a los hombres, con síntomas que suelen aparecer en la primera infancia. El número de personas diagnosticadas con DMD también está aumentando, y esta creciente prevalencia ha creado una necesidad de tratamientos y terapias eficaces, ya que la población mundial sigue creciendo.
La creciente prevalencia de DMD también ha aumentado los esfuerzos de promoción de pacientes y profesionales de la salud. Estos grupos desempeñan un papel vital en la sensibilización sobre DMD, la promoción de la financiación de la investigación y la aprobación más rápida de posibles tratamientos. La comunidad DMD está aumentando, por lo tanto, el avance de las tecnologías y las inversiones en esta esfera de la salud también está aumentando
- Introducción de terapias de novela para DMDTrastorno
El surgimiento de enfoques innovadores de tratamiento conduce al aumento de la atención de DMD y contribuye significativamente a la expansión del mercado. Las opciones de tratamiento tradicionales se centraron principalmente en la gestión de los síntomas y la atención de apoyo. Sin embargo, la introducción de nuevas terapias representa un cambio de paradigma a medida que pretenden abordar las mutaciones genéticas de raíz responsables de DMD.
Además, las drogas exon-skipping han surgido como otra clase prometedora de terapias para DMD. Estos fármacos están diseñados para "esquipar" exones específicos en el gen de distropina, permitiendo la producción de una proteína de distropina truncada pero parcialmente funcional. Estos medicamentos pueden retrasar significativamente la progresión de la enfermedad y mejorar la calidad de vida de las personas con DMD. El desarrollo y la aprobación de estas terapias han proporcionado nuevas expectativas a los pacientes con DMD y se espera además impulsar el crecimiento del mercado.
Oportunidad
- Development of Healthcare Infrastructure and Increasing Investment
Los pacientes con DMD pueden diagnosticarse antes con una infraestructura sanitaria más fuerte, incluyendo hospitales bien equipados e instalaciones de diagnóstico. El diagnóstico precoz permite la intervención oportuna y la iniciación del tratamiento, la progresión de enfermedades potencialmente lentas y la mejora de los resultados del paciente. Los sistemas de salud desarrollados suelen tener centros especializados y clínicas dedicadas a enfermedades raras, como DMD. Estos centros ofrecen atención integral, incluido el acceso a profesionales especializados de la salud, terapia física y servicios de apoyo, que pueden mejorar la calidad de vida de los pacientes con DMD.
Los sistemas de salud desarrollados a menudo ofrecen una amplia gama de servicios de apoyo, como físicos yterapia ocupacional, dispositivos de asistencia y asesoramiento, que pueden mejorar significativamente la calidad de vida de los pacientes con DMD. Los gobiernos, los inversores privados y las organizaciones filantrópicas tienen más probabilidades de invertir en el desarrollo de drogas para enfermedades raras, como DMD cuando hay una infraestructura sanitaria bien establecida. Esta inversión puede apoyar la investigación, ensayos clínicos y el desarrollo de terapias innovadoras.
Restraint/ Challenge
- Disponibilidad limitada de tratamientos DMD Debido a la falta de tecnología de avance
Ha habido opciones de tratamiento limitadas disponibles para DMD, dejando a los pacientes y sus familias con pocas opciones para reducir la progresión de la enfermedad o mejorar su bienestar general.
El avance en la tecnología suele dar lugar al desarrollo de tratamientos altamente especializados e innovadores para las DMD, como por ejemploterapias genéticaso enfoques de medicina personalizada. Estas terapias de vanguardia son complejas para desarrollar, fabricar y administrar. El desarrollo de terapias genéticas, en particular, implica procesos complejos y técnicas de fabricación especializadas. Estas terapias requieren la modificación o sustitución de genes defectuosos para abordar la causa subyacente de DMD, lo que conduce a altos costos de tratamiento. Además, el limitado número de instalaciones de fabricación capaces de producir terapias genéticas contribuye aún más a su disponibilidad limitada.
La complejidad de los tratamientos avanzados de DMD puede dificultar la fabricación y la administración, contribuyendo aún más a su disponibilidad limitada. Es posible que se necesiten instalaciones especializadas y conocimientos especializados para la producción, y la administración de estos tratamientos podría exigir a profesionales médicos especializados, que pueden ser escasos en algunas regiones.
Novedades recientes
- En marzo de 2023, la Terapéutica Dyne anunció que DYNE-251, una terapéutica investigativa para las mutaciones de distrofia muscular Duchenne (DMD) susceptibles de exon 51 escaneo, fue otorgada U.S. FDA medicamentos huérfanos y raras denominaciones de enfermedades pediátricas. DYNE-251 está siendo evaluado en el ensayo clínico Fase 1/2 DELIVER. Esto ayuda a la organización a aumentar su categoría de productos y los ingresos generales.
- En agosto de 2022, FibroGen, Inc. anunció datos de primera línea del ensayo de fase 3 LELANTOS-2 de pamrevlumab para el tratamiento de pacientes ambulatorios con DMD sobre corticosteroides sistémicos de fondo. Esto ayudó a la empresa a fortalecer su cartera de oleoductos.
Global Duchenne Muscular Dystrophy Treatment Market Scope
El mercado global de tratamiento de distrofia muscular duchenne se segmenta en cinco segmentos notables basados en tipo de tratamiento, terapia, ruta de administración, usuario final y canal de distribución. El crecimiento entre estos segmentos le ayudará a analizar segmentos de crecimiento más bajos en las industrias y a proporcionar a los usuarios una valiosa visión general del mercado y perspectivas de mercado para ayudarles a tomar decisiones estratégicas para identificar aplicaciones de mercado básicos.
Tipo de tratamiento
- Terapias de base molecular
- Terapia esteroides
- Otros
Sobre la base del tipo de tratamiento, el mercado se segmenta en terapias basadas en moleculares, terapia con esteroides y otros.
Terapia
- Exon Skipping Approach
- Represión de la mutación
- Terapias capturadas por Dystrophin
Sobre la base de la terapia, el mercado se segmenta en el enfoque exon saltando, la supresión de mutaciones y las terapias ditrocinadas.
Ruta de la Administración
- Oral
- Parenteral
- Otros
Sobre la base de la vía de administración, el mercado se segmenta en oral, parenteral y otros.
Usuario final
- Hospitales
- Home Healthcare
- Clínicas especializadas
- Otros
Sobre la base del usuario final, el mercado se segmenta en hospitales, atención médica en el hogar, clínicas especializadas y otros.
Distribución
- Farmacia hospitalaria
- Farmacia en línea
- Farmacia minorista
Sobre la base del canal de distribución, el mercado se segmenta en farmacia hospitalaria, farmacia en línea, farmacia minorista.
Global Duchenne Muscular Dystrophy Treatment Market Regional Analysis/Insights
El mercado global de tratamiento de distrofia muscular duchenne se segmenta en cinco segmentos notables basados en tipo de tratamiento, terapia, ruta de administración, usuario final y canal de distribución.
Los países cubiertos en este informe del mercado mundial de tratamiento de la distrofia muscular duchena son Estados Unidos, Canadá, México, Alemania, Francia, Reino Unido, Italia, España, Rusia, Turquía, Bélgica, Países Bajos, Suiza, Resto de Europa, Japón, China, Corea del Sur, India, Australia, Singapur, Tailandia, Malasia, Indonesia, Filipinas, Resto de Asia-Pacífico, Brasil, Argentina, Resto de América del Sur, Sudáfrica, Arabia Saudita, Egipto.
Se espera que Estados Unidos domine en América del Norte debido a la creciente conciencia y proyección de DMD. Se espera que Alemania prevalezca en Europa debido a la creciente prevalencia de la distrofia muscular y la penetración de nuevos avances tecnológicos. Se espera que China domine a Asia y el Pacífico ya que las iniciativas estratégicas de los principales agentes del mercado se están expandiendo significativamente.
En la sección nacional del informe también se proporcionan factores de impacto individual en el mercado y cambios en la regulación del mercado que afectan las tendencias actuales y futuras del mercado. Los datos como el análisis de la cadena de valor aguas abajo y aguas arriba, las tendencias técnicas, el análisis de las cinco fuerzas del porteador y los estudios de casos son algunos de los puntos utilizados para prever el escenario del mercado para países individuales. Asimismo, se considera la presencia y disponibilidad de marcas mundiales y sus retos a los que se enfrentan debido a la competencia amplia o escasa de las marcas locales y nacionales, los efectos de los aranceles internos y las rutas comerciales, al tiempo que se proporciona un análisis de los datos de los países.
Paisaje competitivo y Duchenne mundial Mercado de tratamiento de la distrofia muscular Compartir análisis
El mercado mundial de tratamiento de distrofia muscular duchenne proporciona detalles del competidor. Los detalles incluidos son la visión general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, las nuevas iniciativas de mercado, la presencia mundial, los sitios de producción e instalaciones, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la anchura y amplitud del producto y el dominio de la aplicación. Los puntos de datos arriba proporcionados sólo están relacionados con el enfoque de las empresas relacionados con el mercado.
Los principales jugadores de mercado que operan en el mercado mundial de tratamiento de distrofia muscular de duchenne son Sarepta Therapeutics, Inc., GSK plc., Capricor Therapeutics, Inc., Dyne Therapeutics, Solid Biosciences Inc., BioMarin, Stealth BioTheeutics Inc., COvidity BioPherma, ReveraGen BioPHAHARMA
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCCIÓN
1.1 OBJETIVOS DEL ESTUDIO
1.2 DEFINICIÓN DEL MERCADO
1.3 Examen general del memorando de entendimiento de los derechos humanos de los pueblos indígenas
1.4 CURRENCY AND PRICING
1.5 LIMITACIONES
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 ÁMBIÉN GEOGRÁFICO
2.3 AÑOS ESTUDIOS PARA EL ESTUDIO
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 ENTREVISTAS PRIMARÍAS CON LEADRES DE OPINION KEY
2.6 MULTIVARIATE MODELLING
2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE
2.8 MARKET END USUER COVERAGE GRID
2.9 GRID DE POSICIÓN DEL MERCADO
2.1 VENDOR SHARE ANALISIS
2.11 FUERZAS SEGUNDARIAS
2.12 ASUNTOS
RESUMEN EJECUTIVO
4 fotos INSIGHTS
4.1 MODELO DE PESTEL
4.2 FIVE FORCES FIVE MODEL DE PORTER
4.3 ANÁLISIS PRINCIPAL
5 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: REGULATIONS
5.1 REGULACIONES EN EE.UU.
5.2 REGULACIONES EN EUROPA
5.3 REGULATCIONES EN AUSTRALIA
5.4 REGULACIONES EN ÁFRICA SUR
5.5 REGULACIONES EN BRASIL
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE AND IMPACT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) DISEASE
6.1.2 INTRODUCCIÓN DE LAS TERAPÍAS DE NOVIA PARA EL DESARME DMD
6.1.3 RISING AWARENESS FOR DMD TREATMENTS
6.1.4 INCREASE IN THE NUMBER OF CLINICAL TRIALS is a RECENT TREND
6.2 RESTRAINTS
6.2.1 AVAILABILIDAD LIMITADA DE LOS TRATAMIENTOS DE DMD QUE DEBAN TECNOLOGÍA
6.2.2 GASTOS DE TRATAMIENTO ALTO
6.3 OPORTUNIDADES
6.3.1 DESARROLLO DE LA INFRASTRUCTURA HEALTHCARE Y INCREASING INVESTMENT
6.3.2 RISING PATIENT INCLINATION TOWARDS PERSONALIZED AND EFFECTIVE THERAPIES
6.3.3 INICIATIVAS ESTRATEGICAS POR LOS PLAYES DE MARCHA DE KEY
6.3.4 APOYO DE GRUPOS ADVOCACIOS PACIENTES SOBRE EL PROCESO DE APROBACIÓN REGULATORIO
6.4
6.4.1 LACK OF STANDARDIZATION IN DMD DIAGNOSIS
6.4.2 CONSIDERACIONES ÉTICAS RELACIONADAS CON LA ALTERACIÓN PERMANENTE DEL CODE GENETIC DEL PACIENTE
7 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE
7.1 Examen general
7.2 Terapias de base molecular
7.2.1 ANTISENSE OLIGONUCLEOTIDE THERAPY
7.2.1.1 EXONDÍAS 51
7.2.1.2 AMONDYS 45
7.2.1.3 VYONDYS 53
7.3 MUTACIÓN NONSENSA
7.3.1.1 Translarna
7.4 THERAPY STEROID
7.4.1 PREDNISONE
7.4.2 DEFLAZACORT
7.5 OTHERS
8 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY
8.1 Examen general
8.2 EXON SKIPPING APPROACH
8.2.1 MULTI-EXON SKIPPING APPROACH
8.2.2 SINGLE-EXON SKIPPING APPROACH
8.3 SUPPRESSIÓN DE MUTACIÓN
8.4 Temas iniciados por la Oficina
8.4.1 GENE THERAPIES
8.4.2 Terapias CELL
8.4.2.1 Edición de genes
8.4.2.2 Adición de genes
9 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
9.1 Examen general
9.2 PARENTERAL
9.3 ORAL
9.4 OTROS
10 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER
10.1 Examen general
10.2 HOSPITALS
10.3 CLINICS ESPECIALES
10.4 HOMECARE
10.5 OTROS
11 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL
11.1 Examen general
11.2 HOSPITAL PHARMACY
11.3 RETAIL PHARMACY
11.4 PHARMACY ONLINE
12 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION
12.1 Examen general
12.2 NORTH AMERICA
12.2.1 Estados Unidos
12.2.2 CANADA
12.2.3 MEXICO
12,3 EUROPA
12.3.1 ALEMANIA
12.3.2 FRANCIA
12.3.3 U.K.
12.3.4
12.3.5 ESPAÑA
12.3.6 RUSSIA
12.3.7 TURKEY
12.3.8 BELGIUM
12.3.9 NETHERLANDS
12.3.10 SUIZA
12.3.11 Prueba de EUROPA
12.4 ASIA-PACIFIC
12.4.1 CHINA
12.4.2 JAPÓN
12.4.3 INDIA
12.4.4.
12.4.5 AUSTRALIA
SINGAPORE
12.4.7 THAILAND
12.4.8 MALASIA
12.4.9 INDONESIA
12.4.10 PHILIPPINES
12.4.11 REST OF ASIA-PACIFIC
12,5 SOUTH AMERICA
12.5.1 BRASIL
12.5.2 ARGENTINA
12.5.3 REST OF SOUTH AMERICA
12.6 MIDDLE EAST AND AFRICA
12.6.1 SOUTH AFRICA
12.6.2 ARABIA SAUDITA
12.6.3 U.A.E
12.6.4 EGIPTO
12.6.5 ISRAEL
12.6.6 REST OF MIDDLE EAST AND AFRICA
13 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALISIS: GLOBAL
14 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALISIS: EUROPA
16 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALISIS: ASIA-PACIFIC
17 ANÁLISIS DE SWOT
18 EMPRESAS
18.1 SAREPTA THERAPEUTICS, INC.
18.1.1 SNAPSHOT
18.1.1 ANÁLISIS REVENIDO
18.1.2 COMPANY SHARE ANALISIS
18.1.3 PRODUCTO PORTFOLIO
18.1.4 PIPELINE PORTFOLIO
18.1.5 ACONTECIMIENTOS RECIENTES
18.2 F. HOFFMANN-LA ROCHE LTD
18.2.1 SNAPSHOT
18.2.2 ANÁLISIS REVENIDO
18.2.3 COMPANY SHARE ANALISIS
18.2.4 PRODUCTO PORTFOLIO
18.2.5 PIPELINE PORTFOLIO
18.2.6 ACONTECIMIENTOS RECIENTES
18.3 TERAPEUTICS PTC.
18.3.1 SNAPSHOT
18.3.2 ANÁLISIS REVENIDO
18.3.3 COMPANY SHARE ANALISIS
18.3.4 PRODUCTO PORTFOLIO
18.3.5 DESARROLLO RECIENTE
18.4 PFIZER INC.
18.4.1 SNAPSHOT
18.4.2 ANÁLISIS REVENIDO
18.4.3 COMPANY SHARE ANALISIS
18.4.4 PIPELINE PORTFOLIO
18.4.5 PRODUCTO PORTFOLIO
18.4.6 DESARROLLO RECIENTE
18.5 AKASHI RX
18.5.1 SNAPSHOT
18.5.2 PIPELINE PORTFOLIO
18.5.3 ACONTECIMIENTOS RECIENTES
18.6 AVIDITY BIOSCIENCES
18.6.1 SNAPSHOT
18.6.2 ANÁLISIS REVENIDO
18.6.3 PIPELINE PORTFOLIO
18.6.4 ACONTECIMIENTOS RECIENTES
18.7 BIOMARIN
18.7.1 SNAPSHOT
18.7.2 ANÁLISIS REVENIDO
18.7.3 PIPELINE PORTFOLIO
18.7.4 ACONTECIMIENTOS RECIENTES
18.8 Terapéuticas del CAPRICOR, INC.
18.8.1 SNAPSHOT
18.8.2 PIPELINE PORTFOLIO
18.8.3 ACONTECIMIENTOS RECIENTES
18,9 DYNE THERAPEUTICS
18.9.1 SNAPSHOT
18.9.2 PIPELINE PORTFOLIO
18.9.3 ACONTECIMIENTOS RECIENTES
18.1 FIBROGEN, INC.
18.10.1 SNAPSHOT
18.10.2 ANÁLISIS REVENIDO
18.10.3 PIPELINE PORTFOLIO
18.10.4 DESARROLLO RECIENTE
18.11 ITALFARMACO S.P.A.
18.11.1
18.11.2 PIPELINE PORTFOLIO
18.11.3 DESARROLLO RECIENTE
18.12 NS PHARMA, INC.
18.12.1
18.12.2 PIPELINE PORTFOLIO
18.12.3 ACONTECIMIENTOS RECIENTES
18.13 REVERAGEN BIOPHARMA, INC.
18.13.1
18.13.2 PIPELINE PORTFOLIO
18.13.3 DESARROLLO RECIENTE
18.14 SANTHERA PHARMACEUTICALS
18.14.1
18.14.2 ANÁLISIS REVENIDO
18.14.3 PIPELINE PORTFOLIO
18.14.4 DESARROLLO RECIENTE
18.15 TAIHO PHARMACEUTICAL CO., LTD.
18.15.1
18.15.2 PIPELINE PORTFOLIO
18.15.3 ACONTECIMIENTOS RECIENTES
18.16 SOLID BIOSCIENCES INC.
18.16.1
18.16.2 PIPELINE PORTFOLIO
18.16.3 DESARROLLO RECIENTE
18.17 STEALTH BIOTHERAPEUTICS INC
18.17.1
18.17.2 PIPELINE PORTFOLIO
18.17.3 DESARROLLO RECIENTE
19 CUESTIÓN
20 INFORMES CONEXOS
Lista de Tablas
CUADRO 1 LISTA DE PRECIOS PARA LOS DROGAS APROBADOS DEL MERCADO DE TRATAMIENTO DE DUCHENNE MUSCULAR
TABLE 2 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 3 THERAPIES GLOBAL MOLECULAR-BASED en DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
CUADRO 4 THERAPIES GLOBAL MOLECULAR-BASED en DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 5 GLOBAL ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 6 GLOBAL NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 7 GLOBAL STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 8 GLOBAL STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 9 OTROS GLOBALES EN MERCADO DE TRATAMIENTO DUCHENNE MUSCULAR, POR REGION, 2021-2030 (USTED)
CUADRO 10 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 11 GLOBAL EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 12 GLOBAL EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 13 SUPPRESIÓN DE MUTACIÓN GLOBAL EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
CUADRO 14 TERAPÍAS GLOBAL DYSTROPHIN-TREATMENT MARKET DYSTROPHY, POR REGION, 2021-2030 (USD THOUSAND)
CUADRO 15 THERAPIES DE DYSTROPHIN-TARGETED DYSTROPHY DE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR THERAPY, 2021-2030 (USTED)
CUADRO 16 THERAPIES GLOBAL CELL IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 17 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION , 2021-2030 (USD THOUSAND)
CUADRO PARENTERAL 18 GLOBAL EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR REGION, 2021-2030 (USTED)
CUADRO 19 GLOBAL ORAL IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
CUADRO 20 OTROS GLOBALES EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
CUADRO 21 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USERS, 2021-2030 (USD THOUSAND)
CUADRO 22 HOSPITALS GLOBAL EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
CUADRO 23 GLOBAL SPECIALITY CLINICS IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
CUADRO 24 GLOBAL HOMECARE EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
CUADRO 25 OTROS GLOBALES EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
CUADRO 26 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
CUADRO 27 PHARMACÍA DE HOSPITAL GLOBAL en DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
CUADRO 28 GLOBAL RETAIL PHARMACY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
CUADRO 29 GLOBAL ONLINE PHARMACY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
TABLE 30 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)
CUADRO 31 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) COUNTRY
TABLE 32 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 33 NORTH AMERICA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 34 NORTH AMERICA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 35 NORTH AMERICA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 36 NORTH AMERICA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 37 NORTH AMERICA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 38 NORTH AMERICA STEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (US$ THOUSAND)
CUADRO 39 NORTH AMERICA STEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 40 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 41 NORTH AMERICA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 42 NORTH AMERICA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 43 THERAPIES NORTH AMERICA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 44 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 45 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 46 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 47 U.S. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 48 THERAPIES MOLECULAR-BASED en DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 49 U.S. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 50 U.S. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 51 U.S. ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 52 U.S. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 53 U.S. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 54 U.S. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 55 US STEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 56 US STEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 57 US STEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 58 U.S.DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 59 U.S. EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (US$ THOUSAND)
CUADRO 60 THERAPIES DE DYSTROPHIN-TREATMENT DE DUCHENNE MUSCULAR DYSTROPHY MARKET, POR THERAPY, 2021-2030 (USTED)
CUADRO 61 THERAPIES DE US CELL EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR THERAPY, 2021-2030 (USTED)
CUADRO 62 U.S. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 63 U.S. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 64 U.S. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
CUADRO 65 CANADA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 66 THERAPIES CANADA MOLECULAR-BASED en DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 67 CANADA ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 68 CANADA ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 69 CANADA ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 70 CANADA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 71 CANADA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 72 CANADA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 73 CANADA STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 74 CANADA STEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 75 CANADA STEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 76 CANADA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 77 CANADA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 78 THERAPIES CANADA DYSTROPHIN-TARGETED EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR THERAPY, 2021-2030 (US$ THOUSAND)
CUADRO 79 THERAPIES CELL CANADA EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR THERAPY, 2021-2030 (USTED)
CUADRO 80 CANADA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 81 CANADA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 82 CANADA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
CUADRO 83 MÉXICO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 84 MÉXICO MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 85 MÉXICO ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 86 MÉXICO ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 87 MÉXICO ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 88 MÉXICO NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 89 MÉXICO NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 90 MÉXICO NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 91 MÉXICO STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 92 MÉXICO STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 93 MÉXICO ESTEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 94 MÉXICO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 95 MÉXICO EXON SKIPPING APPROACH EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR THERAPY, 2021-2030 (US$ THOUSAND)
CUADRO 96 MÉXICO DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 97 MÉXICO CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 98 MÉXICO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 99 MÉXICO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 100 MÉXICO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
CUADRO 101 EUROPA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
CUADRO 102 EUROPA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 103 EUROPA TERAPIES MOLECULAR-BASED en DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 104 EUROPA ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 105 EUROPA ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 106 EUROPA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 107 EUROPA MUTACIÓN DE NONSENSA EN EL MERCADO DE TRATAMIENTO MUSCULAR DYSTROPHY, POR TYPE DE TRATAMIENTO, 2021-2030 (VOLUME)
TABLE 108 EUROPE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 109 EUROPEO ESTEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 110 EUROPA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 111 EUROPA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 112 EUROPA TERAPÍAS TERMINADAS DE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR THERAPY, 2021-2030 (US$ THOUSAND)
CUADRO 113 EUROPA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 114 EUROPA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 115 EUROPA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 116 EUROPA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 117 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 118 GERMANY MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 119 GERMANY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 120 GERMANY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 121 GERMANY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 122 GERMANY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 123 GERMANY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 124 GERMANY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 125 GERMANY STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 126 GERMANY STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 127 GERMANY STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 128 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 129 GERMANY EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 130 GERMANY DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 131 GERMANY CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 132 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 133 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 134 GERMANY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
CUADRO 135 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 136 FRANCE MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 137 FRANCE ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 138 FRANCE ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 139 FRANCE ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 140 FRANCE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 141 FRANCE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 142 FRANCE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 143 FRANCE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 144 FRANCE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 145 FRANCE STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 146 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 147 FRANCE EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 148 FRANCE DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 149 FRANCIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 150 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 151 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 152 FRANCE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
CUADRO 153 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 154 Terapias con base MOLECULAR en DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (US$ THOUSAND)
CUADRO 155 U.K. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 156 U.K. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 157 U.K. ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 158 U.K. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 159 U.K. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 160 U.K. NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 161 U.K. STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 162 U.K. STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 163 U.K. STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 164 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 165 U.K. EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 166 U.K. DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 167 U.K. CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 168 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 169 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 170 U.K. DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
CUADRO 171 ITALY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 172 TERAPÍAS MOLECULAR-BASED en DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (US$ THOUSAND)
CUADRO 173 ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 174 ITALIA ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 175 ITALIA ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 176 ITALY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 177 MUTACIÓN DE NONSENSA DE ITALIA EN EL MERCADO DE TRATAMIENTO MUSCULAR DYSTROPHY, POR TYPE DE TRATAMIENTO, 2021-2030 (VOLUME)
CUADRO 178 MUTACIÓN DE NONSENSAJE DE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 179 ITALY STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 180 ITALIA ESTEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 181 ITALIA ESTEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 182 ITALYDUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 183 ITALIA EXON SKIPPING APPROACH EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR THERAPY, 2021-2030 (US$ THOUSAND)
CUADRO 184 TERAPÍAS DE ITALIA DYSTROPHIN DE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR THERAPY, 2021-2030 (US$ THOUSAND)
CUADRO 185 TERAPÍAS DE CELL ITALIA DE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 186 ITALY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 187 ITALY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 188 ITALY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 189 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 190 SPAIN MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 191 SPAIN ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 192 ESPAÑA ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 193 ESPAÑA ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 194 SPAIN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 195 SPAIN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 196 SPAIN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 197 SPAIN STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 198 SPAIN STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 199 SPAIN STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 200 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 201 SPAIN EXON SKIPPING APPROACH in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 202 SPAIN DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 203 TREATMENTO DE ESPAÑA CELL THERAPIES EN DUCHENNE MUSCULAR DYSTROPHY MARKET, POR THERAPY, 2021-2030 (US$ THOUSAND)
TABLE 204 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 205 ESPAÑA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 206 SPAIN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 207 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 208 RUSSIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 209 RUSSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 210 RUSSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 211 RUSSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 212 RUSSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 213 RUSSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 214 RUSSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 215 RUSSIA STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 216 RUSSIA STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 217 RUSSIA STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 218 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 219 RUSSIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (US$ THOUSAND)
CUADRO 220 RUSSIA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 221 RUSSIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 222 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 223 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 224 RUSSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 225 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 226 TURKEY MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 227 TURKEY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 228 TURKEY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 229 TURKEY ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 230 TURKEY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 231 TURKEY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 232 TURKEY NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 233 TURKEY STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 234 TURKEY STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 235 TURKEY STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 236 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 237 TURKEY EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 238 TURKEY DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 239 TURKEY CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 240 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 241 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 242 TURKEY DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 243 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 244 TERAPIOS BELGIUM MOLECULAR-BASED en DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 245 BELGIUM ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 246 BELGIUM ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 247 BELGIUM ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 248 BELGIUM NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 249 BELGIUM NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 250 BELGIUM NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 251 BELGIUM STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 252 BELGIUM STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 253 TERAPY DE ESTEROID BELGIUM EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 254 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 255 BELGIUM EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 256 TEMAGIUM DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR THERAPY, 2021-2030 (USTED)
TABLE 257 THERAPIES BELGIUM CELL en DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 258 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 259 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 260 BELGIUM DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
CUADRO 261 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 262 NETHERLANDS MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 263 NETHERLANDS ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 264 NETHERLANDS ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 265 NETHERLANDS ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 266 NETHERLANDS NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 267 NETHERLANDS NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 268 NETHERLANDS NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 269 NETHERLANDS STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 270 NETHERLANDS STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 271 NETHERLANDS STEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 272 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 273 NETHERLANDS EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 274 NETHERLANDS DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 275 NETHERLANDS CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 276 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 277 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 278 NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 279 SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 280 TRETAÑA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 281 SUIZA ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 282 SUIZA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 283 SUIZA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 284 SWITZERLAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 285 SWITZERLAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 286 NONSENSE DE SUIZA MUTACIÓN EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 287 SWITZERLAND STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 288 SWITZERLAND STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 289 SWITZERLAND STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 290 SWITZERLANDDUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 291 SWITZERLAND EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 292 TRETAÑOS DE SUIZA DYSTROPHIN-TARGETED THERAPIES EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR THERAPY, 2021-2030 (USTED)
TABLE 293 THERAPIES SWITZERLAND CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 294 SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 295 SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 296 SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 297 REST OF EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 298 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR PAÍS, 2021-2030 (USTED)
CUADRO 299 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 300 ASIA-PACIFIC MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 301 ASIA-PACIFIC ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 302 ASIA-PACIFIC ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 303 ASIA-PACIFIC NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 304 ASIA-PACIFIC NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 305 ASIA-PACIFIC STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 306 ASIA-PACIFIC STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 307 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 308 ASIA-PACIFIC EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 309 ASIA-PACIFIC DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 310 THERAPIES ASIA-PACIFIC CELL EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR THERAPY, 2021-2030 (US$ THOUSAND)
TABLE 311 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 312 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 313 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
CUADRO 314 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 315 TERAPÍAS MOLECULAR-BASED en DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (US$ THOUSAND)
CUADRO 316 CHINA ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 317 CHINA ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 318 CHINA ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 319 CHINA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 320 CHINA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 321 CHINA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 322 CHINA STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 323 CHINA STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 324 CHINA STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 325 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 326 CHINA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 327 TRETAMIENTO DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USTED)
CUADRO 328 THERAPIES CHINA CELL en DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR THERAPY, 2021-2030 (USTED)
CUADRO 329 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 330 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 331 CHINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 332 JAPÓN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 333 JAPÓN MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 334 JAPÓN ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 335 JAPÓN ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 336 JAPÓN ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 337 JAPÓN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 338 JAPÓN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 339 JAPÓN NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 340 JAPÓN ESTEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 341 JAPAN STEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 342 JAPÓN ESTEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 343 JAPÓN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 344 JAPÓN EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 345 JAPÓN DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 346 JAPÓN CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 347 JAPÓN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 348 JAPÓN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 349 JAPÓN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
CUADRO 350 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 351 INDIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 352 INDIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 353 INDIA ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 354 INDIA ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 355 INDIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 356 INDIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 357 INDIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 358 INDIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 359 INDIA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 360 INDIA STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 361 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 362 INDIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 363 INDIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 364 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 365 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 366 INDIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 367 SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 368 TREATMENTO DE COREA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 369 ANTISENSA OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 370 ANTISENSA OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 371 ANTISENSA OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 372 SOUTH KOREA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 373 SOUTH KOREA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 374 SOUTH KOREA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 375 SOUTH KOREA STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 376 SOUTH KOREA STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 377 SOUTH KOREA STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 378 SOUTH KOREADUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 379 SOUTH KOREA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USTED)
CUADRO 380 SOUTH KOREA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 381 TREATMENTO DE KOREA SOUTH, POR THERAPY, 2021-2030 (USD THOUSAND)
TABLE 382 SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 383 SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 384 SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 385 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 386 AUSTRALIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 387 AUSTRALIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 388 AUSTRALIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 389 AUSTRALIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 390 AUSTRALIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 391 AUSTRALIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 392 AUSTRALIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 393 AUSTRALIA STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 394 AUSTRALIA STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 395 AUSTRALIA STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 396 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR THERAPY, 2021-2030 (USD THOUSAND)
TABLE 397 AUSTRALIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 398 AUSTRALIA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 399 AUSTRALIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 400 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 401 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 402 AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 403 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 404 SINGAPORE MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 405 ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 406 ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 407 ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 408 SINGAPORE NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (US$ THOUSAND)
CUADRO 409 MUTACIÓN SINGAPORE NONSENSE EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 410 MUTACIÓN SINGAPORE NONSENSE EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 411 SINGAPORE STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 412 SINGAPORE STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 413 SINGAPORE ESTEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 414 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 415 SINGAPORE EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 416 TERCERAS DE SINGAPORE DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 417 THERAPIES SINGAPORE EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR THERAPY, 2021-2030 (USD THOUSAND)
TABLE 418 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 419 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 420 SINGAPORE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
CUADRO 421 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 422 THERAPIES MOLECULAR-BASED en DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (US$ THOUSAND)
CUADRO 423 THAILAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 424 TEAILAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 425 THAILAND ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 426 THAILAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 427 THAILAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 428 THAILAND NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 429 THAILAND STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 430 THAILAND STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 431 THAILAND STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 432 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 433 THAILAND EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 434 TERCERA TREATMENTO DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 435 THERAPIES DE THAILAND CELL IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 436 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 437 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 438 THAILAND DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
CUADRO 439 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 440 MALAYSIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 441 MALAYSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 442 MALAYSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 443 MALAYSIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 444 MALAYSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (US$ THOUSAND)
CUADRO 445 MALAYSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 446 MALAYSIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 447 MALAYSIA ESTEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (US$ THOUSAND)
CUADRO 448 MALAYSIA ESTEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 449 MALAYSIA ESTEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 450 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 451 MALAYSIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (US$ THOUSAND)
TABLE 452 MALAYSIA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 453 MALAYSIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 454 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 455 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 456 MALAYSIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 457 INDONESIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 458 INDONESIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 459 INDONESIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 460 INDONESIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 461 INDONESIA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 462 INDONESIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 463 INDONESIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 464 INDONESIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 465 INDONESIA STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 466 INDONESIA STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 467 INDONESIA STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 468 INDONESIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 469 INDONESIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 470 INDONESIA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 471 INDONESIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 472 INDONESIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 473 INDONESIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 474 INDONESIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
CUADRO 475 PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 476 PHILIPPINES MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 477 PHILIPPINES ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 478 PHILIPPINES ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 479 PHILIPPINES ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 480 PHILIPPINES NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 481 PHILIPPINES NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 482 PHILIPPINES NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 483 PHILIPPINES STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 484 PHILIPPINES STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 485 PHILIPPINES STEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 486 PHILIPPINESDUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 487 PHILIPPINES EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 488 PHILIPPINES DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 489 PHILIPPINES CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 490 PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 491 PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 492 PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
CUADRO 493 REST OF ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 494 SOUTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR PAÍS, 2021-2030 (USTED)
TABLE 495 SOUTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 496 TERCERAS DE AMERICA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 497 ANTISENSA OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 498 AMERICA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 499 MUTACIÓN SOUTH AMERICA NONSENSE EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (US$ THOUSAND)
TABLE 500 SOUTH AMERICA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 501 SOUTH AMERICA STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 502 SOUTH AMERICA STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 503 SOUTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 504 AMERICA EXON SKIPPING APPROACH EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR THERAPY, 2021-2030 (US$ THOUSAND)
CUADRO 505 TERCERAS DE AMERICA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 506 TERAPÍAS CELL SOUTH AMERICA DE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR THERAPY, 2021-2030 (US$ THOUSAND)
CUADRO 507 SOUTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 508 SUR AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 509 SOUTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
CUADRO 510 BRAZIL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 511 BRAZIL MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 512 BRAZIL ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 513 BRAZIL ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 514 BRAZIL ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 515 BRAZIL NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 516 BRASIL NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 517 BRASIL NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 518 BRAZIL STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 519 BRAZIL STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 520 BRAZIL STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 521 BRAZIL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 522 BRAZIL EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (US$ THOUSAND)
CUADRO 523 THERAPIES DE DYSTROPHIN DE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR THERAPY, 2021-2030 (USTED)
CUADRO 524 THERAPIES BRAZIL EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 525 BRAZIL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 526 BRASIL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 527 BRAZIL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
CUADRO 528 ARGENTINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 529 ARGENTINA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 530 ARGENTINA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 531 ARGENTINA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 532 ARGENTINA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 533 ARGENTINA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 534 ARGENTINA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 535 ARGENTINA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 536 ARGENTINA STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 537 ARGENTINA STEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 538 ARGENTINA STEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 539 ARGENTINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 540 ARGENTINA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (US$ THOUSAND)
TABLE 541 ARGENTINA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 542 ARGENTINA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 543 ARGENTINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 544 ARGENTINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 545 ARGENTINA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
CUADRO 546 REST OF SOUTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 547 MIDDLE EAST AND AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)
CUADRO 548 MIDDLE EAST AND AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 549 MIDDLE EAST AND AFRICA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 550 MIDDLE EAST AND AFRICA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 551 MIDDLE EAST AND AFRICA ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 552 MIDDLE EAST AND AFRICA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 553 MIDDLE EAST AND AFRICA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 554 MIDDLE EAST AND AFRICA STEROID THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 555 MIDDLE EAST AND AFRICA STEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 556 MIDDLE EAST AND AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 557 MIDDLE EAST AND AFRICA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 558 MIDDLE EAST AND AFRICA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 559 MIDDLE EAST AND AFRICA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 560 MIDDLE EAST AND AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 561 MIDDLE EAST AND AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 562 MIDDLE EAST AND AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 563 SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 564 THERAPIES SOUTH AFRICA MOLECULAR-BASED en DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 565 ANTISENSA OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 566 ANTISENSA OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 567 ANTISENSA OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 568 SOUTH AFRICA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 569 MUTACIÓN DE NONSENSA DE SUDÁFRICA DE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 570 SOUTH AFRICA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 571 SOUTH AFRICA STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 572 SUR ÁFRICA ESTEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 573 SOUTH AFRICA STEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 574 SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 575 APARTAMENTO EXON SKIPPING EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR THERAPY, 2021-2030 (USTED)
CUADRO 576 TERCERAS DE AFRICA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 577 TERAPÍAS DE CELL SOUTH AFRICA EN MERCADO DE TRATAMIENTO DUCHENNE MUSCULAR, POR THERAPY, 2021-2030 (US$ THOUSAND)
TABLE 578 SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
TABLE 579 SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 580 SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 581 SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 582 SAUDI ARABIA MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 583 ARABIA SAUDIO ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USTED THOUSAND)
CUADRO 584 ARABIA SAUDIO ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 585 ARABIA SAUDIO ANTISENSE OLIGONUCLEOTIDE THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 586 SAUDI ARABIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 587 SAUDI ARABIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 588 SAUDI ARABIA NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 589 SAUDI ARABIA STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 590 SAUDI ARABIA STEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 591 SAUDI ARABIA STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 592 SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 593 SAUDI ARABIA EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 594 ARABIA SAUDITA DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR THERAPY, 2021-2030 (USTED)
TABLE 595 SAUDI ARABIA CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
TABLE 596 SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 597 ARABIA SAUDIO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
TABLE 598 SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 599 U.A.E DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 600 U.A.E MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 601 U.A.E ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 602 U.A.E ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 603 U.A.E ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 604 U.A.E NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 605 U.A.E NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 606 U.A.E NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 607 U.A.E STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 608 U.A.E STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 609 U.A.E STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 610 U.A.E DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 611 U.A.E EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 612 U.A.E DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 613 U.A.E CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 614 U.A.E DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 615 U.A.E DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 616 U.A.E DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
TABLE 617 EGYPT DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 618 EGIPTO MOLECULAR-BASED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 619 EGIPTO ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 620 EGIPTO ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 621 EGIPTO ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 622 EGIPTO NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (US$ THOUSAND)
CUADRO 623 EGIPTO NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 624 EGIPTO NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 625 EGYPT STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 626 EGIPTO STEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 627 EGIPTO ESTEROID THERAPY EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 628 EGIPTO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 629 EGIPPING EXON SKIPPING APPROACH EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (US$ THOUSAND)
CUADRO 630 EGIPTO DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 631 Terapias de CELL EGIPTO en DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, POR THERAPY, 2021-2030 (USD THOUSAND)
TABLE 632 EGYPT DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 633 EGIPTO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 634 EGIPTO DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
CUADRO 635 ISRAEL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 636 THERAPIES MOLECULAR-BASED en DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USTED)
CUADRO 637 ISRAEL ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 638 ISRAEL ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 639 ISRAEL ANTISENSE OLIGONUCLEOTIDE THERAPY IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 640 ESTRAEL NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
CUADRO 641 NORMAS DE ISRAEL MUTATION EN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
CUADRO 642 ESTRAEL NONSENSE MUTATION IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
TABLE 643 ISRAEL STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
TABLE 644 ISRAEL STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)
TABLE 645 ISRAEL STEROID THERAPY in DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)
CUADRO 646 ISRAEL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 647 ISRAEL EXON SKIPPING APPROACH IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (US$ THOUSAND)
CUADRO 648 ISRAEL DYSTROPHIN-TARGETED THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 649 THERAEL CELL THERAPIES IN DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY THERAPY, 2021-2030 (USD THOUSAND)
CUADRO 650 ISRAEL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)
CUADRO 651 ISRAEL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)
CUADRO 652 ISRAEL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)
CUADRO 653 REST OF MIDDLE EAST AND AFRICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)
Lista de figuras
FIGURE 1 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: SEGMENTATION
FIGURE 2 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 8 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: SEGMENTATION
FIGURE 11 La prevalencia y el cumplimiento de DUCHENNE MUSCULAR DYSTROPHY (DMD) Y la INTRODUCCIÓN DE LAS ARMAS DE NOVIA PARA EL DEshonrado de DMO se EXPERITO PARA LA GRUPO DE LA DUCHENNE MUSCULAR DYSTROPHY TREATMENTO DE 2023
FIGURE 12 THERAPIES BASED MOLECULAR SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET IN 2023 AND 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET
FIGURE 14 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY TREATMENT TYPE , 2022
FIGURE 15 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND)
FIGURE 16 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2023-2030)
FIGURE 17 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 18 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY THERAPY, 2022
FIGURE 19 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY THERAPY, 2023-2030 (USD THOUSAND)
FIGURE 20 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY THERAPY, CAGR (2023-2030)
FIGURE 21 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY THERAPY, LIFELINE CURVE
FIGURE 22 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 23 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND)
FIGURE 24 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 25 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 26 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY END USER, 2022
FIGURE 27 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND)
FIGURE 28 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY END USER, CAGR (2023-2030)
FIGURE 29 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 31 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)
FIGURE 32 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 33 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET SNAPSHOT
FIGURE 35 GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: COMPANY SHARE 2022 (%)
FIGURE 36 NORTH AMERICA DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: COMPANY SHARE 2022 (%)
FIGURE 37 EUROPE DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: COMPANY SHARE 2022 (%)
FIGURE 38 ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET: COMPANY SHARE 2022 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
